glp-1 afib GLP‑1 Therapy Improves Atrial Fibrillation Outcomes After Catheter Ablation, Miller School Study Finds Glucagon-like peptide-1 and atrial fibrillation

The OSA pathway opened in December 2024 after FDA approval based on SURMOUNT-OSA (Malhotra et al

51 Similarly, another meta-analysis demonstrated that patients with T2DM receiving higher doses of tirzepatide exhibited a greater risk of GI adverse events compared to those receiving lower doses, consistent with a clear doseresponse relationship

This is an alarming sign for the GLP-1 industry as the impact of tariffs looms in an already uncertain market, affecting other areas of consumer spending, such as travel, for example

PlexusDx patients often find that tracking these patterns helps them anticipate side effects and adjust meal timing or hydration